Cargando…
A comparison of the neuroprotective efficacy of newly developed oximes (K117, K127) and currently available oxime (obidoxime) in tabun-poisoned rats
The potency of newly developed bispyridinium compounds (K117, K127) to reduce tabun-induced acute neurotoxic signs and symptoms was compared with currently available oxime (obidoxime) using functional observational battery. The neuroprotective effects of atropine alone and atropine combined with one...
Autores principales: | , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Informa Healthcare
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2736538/ https://www.ncbi.nlm.nih.gov/pubmed/19730756 http://dx.doi.org/10.1080/15376510802455362 |
_version_ | 1782171346015354880 |
---|---|
author | Kassa, Jiri Karasova, Jana Zdarova Musilek, Kamil Kuca, Kamil Jung, Young-Sik |
author_facet | Kassa, Jiri Karasova, Jana Zdarova Musilek, Kamil Kuca, Kamil Jung, Young-Sik |
author_sort | Kassa, Jiri |
collection | PubMed |
description | The potency of newly developed bispyridinium compounds (K117, K127) to reduce tabun-induced acute neurotoxic signs and symptoms was compared with currently available oxime (obidoxime) using functional observational battery. The neuroprotective effects of atropine alone and atropine combined with one of three bispyridinium oximes (K117, K127, obidoxime) on rats poisoned with tabun at a sublethal dose (180 μg/kg i.m.; 80% of LD(50) value) were studied. Tabun-induced neurotoxicity was monitored using a functional observational battery and automatic measurement of motor activity at 24 h following tabun challenge. The results indicated that all tested oximes combined with atropine enabled tabun-poisoned rats to survive 24 h following tabun challenge while one tabun-poisoned rats died within 24 h after tabun poisoning when the rats were treated with atropine alone. Newly developed oxime K127 combined with atropine was the most effective in decreasing tabun-induced neurotoxicity in the case of sublethal poisonings among all oximes tested. Nevertheless, the differences of neuroprotective efficacy between K127 and obidoxime are not sufficient to replace obidoxime by K127 for the treatment of acute tabun poisonings. |
format | Text |
id | pubmed-2736538 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2009 |
publisher | Informa Healthcare |
record_format | MEDLINE/PubMed |
spelling | pubmed-27365382009-09-02 A comparison of the neuroprotective efficacy of newly developed oximes (K117, K127) and currently available oxime (obidoxime) in tabun-poisoned rats Kassa, Jiri Karasova, Jana Zdarova Musilek, Kamil Kuca, Kamil Jung, Young-Sik Toxicol Mech Methods Research Article The potency of newly developed bispyridinium compounds (K117, K127) to reduce tabun-induced acute neurotoxic signs and symptoms was compared with currently available oxime (obidoxime) using functional observational battery. The neuroprotective effects of atropine alone and atropine combined with one of three bispyridinium oximes (K117, K127, obidoxime) on rats poisoned with tabun at a sublethal dose (180 μg/kg i.m.; 80% of LD(50) value) were studied. Tabun-induced neurotoxicity was monitored using a functional observational battery and automatic measurement of motor activity at 24 h following tabun challenge. The results indicated that all tested oximes combined with atropine enabled tabun-poisoned rats to survive 24 h following tabun challenge while one tabun-poisoned rats died within 24 h after tabun poisoning when the rats were treated with atropine alone. Newly developed oxime K127 combined with atropine was the most effective in decreasing tabun-induced neurotoxicity in the case of sublethal poisonings among all oximes tested. Nevertheless, the differences of neuroprotective efficacy between K127 and obidoxime are not sufficient to replace obidoxime by K127 for the treatment of acute tabun poisonings. Informa Healthcare 2009-06-30 2009-03 /pmc/articles/PMC2736538/ /pubmed/19730756 http://dx.doi.org/10.1080/15376510802455362 Text en © 2009 Informa UK Ltd http://creativecommons.org/licenses/by/2.0/ This is an open access article distributed under the Supplemental Terms and Conditions for iOpenAccess articles published in Informa Healthcare journals (http://www.informaworld.com/mpp/uploads/iopenaccess_tcs.pdf) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Kassa, Jiri Karasova, Jana Zdarova Musilek, Kamil Kuca, Kamil Jung, Young-Sik A comparison of the neuroprotective efficacy of newly developed oximes (K117, K127) and currently available oxime (obidoxime) in tabun-poisoned rats |
title | A comparison of the neuroprotective efficacy of newly developed oximes (K117, K127) and currently available oxime (obidoxime) in tabun-poisoned rats |
title_full | A comparison of the neuroprotective efficacy of newly developed oximes (K117, K127) and currently available oxime (obidoxime) in tabun-poisoned rats |
title_fullStr | A comparison of the neuroprotective efficacy of newly developed oximes (K117, K127) and currently available oxime (obidoxime) in tabun-poisoned rats |
title_full_unstemmed | A comparison of the neuroprotective efficacy of newly developed oximes (K117, K127) and currently available oxime (obidoxime) in tabun-poisoned rats |
title_short | A comparison of the neuroprotective efficacy of newly developed oximes (K117, K127) and currently available oxime (obidoxime) in tabun-poisoned rats |
title_sort | comparison of the neuroprotective efficacy of newly developed oximes (k117, k127) and currently available oxime (obidoxime) in tabun-poisoned rats |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2736538/ https://www.ncbi.nlm.nih.gov/pubmed/19730756 http://dx.doi.org/10.1080/15376510802455362 |
work_keys_str_mv | AT kassajiri acomparisonoftheneuroprotectiveefficacyofnewlydevelopedoximesk117k127andcurrentlyavailableoximeobidoximeintabunpoisonedrats AT karasovajanazdarova acomparisonoftheneuroprotectiveefficacyofnewlydevelopedoximesk117k127andcurrentlyavailableoximeobidoximeintabunpoisonedrats AT musilekkamil acomparisonoftheneuroprotectiveefficacyofnewlydevelopedoximesk117k127andcurrentlyavailableoximeobidoximeintabunpoisonedrats AT kucakamil acomparisonoftheneuroprotectiveefficacyofnewlydevelopedoximesk117k127andcurrentlyavailableoximeobidoximeintabunpoisonedrats AT jungyoungsik acomparisonoftheneuroprotectiveefficacyofnewlydevelopedoximesk117k127andcurrentlyavailableoximeobidoximeintabunpoisonedrats AT kassajiri comparisonoftheneuroprotectiveefficacyofnewlydevelopedoximesk117k127andcurrentlyavailableoximeobidoximeintabunpoisonedrats AT karasovajanazdarova comparisonoftheneuroprotectiveefficacyofnewlydevelopedoximesk117k127andcurrentlyavailableoximeobidoximeintabunpoisonedrats AT musilekkamil comparisonoftheneuroprotectiveefficacyofnewlydevelopedoximesk117k127andcurrentlyavailableoximeobidoximeintabunpoisonedrats AT kucakamil comparisonoftheneuroprotectiveefficacyofnewlydevelopedoximesk117k127andcurrentlyavailableoximeobidoximeintabunpoisonedrats AT jungyoungsik comparisonoftheneuroprotectiveefficacyofnewlydevelopedoximesk117k127andcurrentlyavailableoximeobidoximeintabunpoisonedrats |